Currently out of the existing stock ratings of Evan Seigerman, 139 are a BUY (58.4%), 80 are a HOLD (33.61%), 19 are a SELL (7.98%).

Evan Seigerman

Work Performance Price Targets & Ratings Chart

Analyst Evan Seigerman, currently employed at BMO, carries an average stock price target met ratio of 67.42% that have a potential upside of 25.71% achieved within 196 days.

Evan Seigerman’s has documented 481 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 04-Dec-2025.

Wall Street Analyst Evan Seigerman

Analyst best performing recommendations are on STSA (SATSUMA PHARMACEUTICALS).
The best stock recommendation documented was for ACRX (ACELRX PHARMACEUTICALS) at 3/24/2020. The price target of $20 was fulfilled within 1 day with a profit of $1 (5.26%) receiving and performance score of 52.63.

Average potential price target upside

of $125.6 (21.58%) on REGN (REGENERON PHARMACEUTICALS).
of $70.18 (76.82%) on IKNA (IKENA ONCOLOGY).
of $70.02 (21.87%) on LLY (ELI LILLY AND COMPANY).

ACRX AcelRx Pharmaceuticals AIMT Aimmune Therapeutics AMGN Amgen BIIB Biogen BMY Bristol-Myers Squibb Company GILD Gilead Sciences GRTX Galera Therapeutics INCY yte LLY Eli Lilly and Company MRTX Mirati Ther NBIX Neurocrine Biosciences PFE Pfizer REGN Regeneron Pharmaceuticals STSA Satsuma Pharmaceuticals VRTX Vertex Pharmaceuticals NUVB Nuvation Bio REPL Replimune Group CADL Candel Therapeutics MGNX MacroGenics MRK Merck mpany GLPG Galapagos NV ADR IKNA Ikena Oncology MORF Morphic GPCR Structure Therapeutics American Depositary Shares IRON Disc Medicine ALDR Alder BioPharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ed Arce (WESTPARK)